firstname.lastname@example.org , The-Christie.Endocrinology@nhs.net
0161 446 3664
0161 446 3667
BA, DPhil (Oxon), MBBS, MRCP (Diabetes and Endocrinology)
Endocrinology, including pituitary disease, metabolic bone disease, late effects of cancer treatment and thyroid eye disease
Started at The Christie (Year)
At The Christie
Clinical lead for:
- DXA and metabolic bone service
- Long term Endocrine complications of cancer treatment
- Turner Syndrome service
- Growth Hormone service
- Pituitary/General Endocrinology
- Joint Transition Clinic with Paediatric Oncology
- Joint Late Effects Clinic with Oncology
At other sites
- Endocrine Consultant Wythenshawe Hospital: General Endocrinology
- Visiting Fellow University of Derby
- Honorary Senior Lecturer University of Manchester
- NIHR CRN Greater Manchester specialty lead: Endocrinology, Metabolism and Lipids
Dr Claire Higham undertook a physiology degree and DPhil at Merton College, Oxford followed by completion of her medical training at Royal Free/University College London.
Her junior doctor training was in London followed by higher specialist training in Manchester including a 3 year clinical research fellowship at Christie Hospital. Dr Higham became an endocrine consultant at the Christie in 2012.
Medical Research Council- CARP (Clinical Academic Research Partnership) Award Holder 2019: Bone Toxicity Following Pelvic Radiotherapy
- Visiting Fellow at University of Derby: DXA reporting for clinicians module
- Member of Royal Osteoporosis Society BDTAP (Bone Densitometry and Assessment Panel)
- Co-lead for Masters Module “Living With and Beyond Cancer” in conjunction with The Christie School of Oncology and University of Manchester
- Publications in The Christie research publications repository
- Higham CE, Thomas JDJ, Bidlingmaier M, Drake WM, Trainer PJ. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol. 2009 161(1):21–5.
- Higham CE, Trainer PJ. Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol. 2008 93(11):1157–69.
- Higham CE, Hull RL, Lawrie L, Shennan KI, Morris JF, Birch NP, et al. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) “amylin” by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 2000 267:4998–5004.
- Higham CE, Jaikaran ET, Fraser PE, Gross M, Clark A. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Lett 2000 470:55–60.
The Christie Private Care
Dr Higham also practises privately at The Christie Private Care
- Contact: 0161 446 3664
- Email: email@example.com